Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Johannes F.E. Mann(Katholische Stiftungshochschule München), Katherine R. Tuttle(Providence Regional Medical Center Everett), Vlado Perkovic(New South Wales Department of Health), Samy Hadjadj(Université de Poitiers), Kenneth W. Mahaffey(Cardiovascular Institute of the South), José Luis Górriz(Universitat de València), Roland E. Schmieder(Universitätsklinikum Erlangen), Heidrun Bosch‐Traberg(University of Copenhagen), Pieter Gillard(Research Foundation - Flanders), Peter Rossing(Steno Diabetes Centers), David M. Charytan(NYU Langone Health), Robert S. Busch(Albany Medical Center Hospital), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Søren Rasmussen(Novo Nordisk (Denmark)), Nicolas Belmar(Novo Nordisk (Denmark)), George L. Bakris(Pennsylvania State System of Higher Education), Thomas Idorn(University of Copenhagen), Linong Ji(Peking University)
Cited by 152
Related Papers
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k